Two Skeptics of Antidepressant Drugs Named to NIH Mental Health Council

Why It Matters

The nominations could shift NIH funding decisions toward anti‑pharmaceutical perspectives, affecting mental‑health research and drug development. It signals a broader effort by the Trump administration to embed its “Make America Healthy Again” agenda in scientific advisory bodies.

Key Takeaways

• Trump admin nominates two antidepressant skeptics to NIMH advisory council.
• Nominees: Laura Delano, founder of Inner Compass, and UCLA’s David Cohen.
• Appointments face ethics review; council currently has only three researcher members.
• Critics warn the moves politicize NIH grant review and research agenda.
• Council influence could rise if no additional scientists are added before September.

Pulse Analysis

The National Institute of Mental Health relies on its National Advisory Mental Health Council to provide a second layer of peer review for grant proposals and to advise on new research programs. Historically, the 18‑member council blends academic researchers with public representatives to balance scientific rigor and community perspectives. In May 2026, the Trump administration moved to place two well‑known antidepressant skeptics—Laura Delano, founder of the Inner Compass Initiative, and David Cohen, a UCLA social‑welfare scholar—on that council. Both have built careers advocating for reduced prescription of psychiatric drugs, and their nominations come amid the administration’s broader “Make America Healthy Again” (MAHA) push to reassess drug‑based treatments.

The potential impact of these appointments extends beyond symbolic representation. The council’s review can sway which projects receive federal funding, influencing the direction of mental‑health research for years to come. Critics, including former NIMH director Joshua Gordon, warn that a council dominated by anti‑pharmaceutical voices may prioritize studies that downplay medication efficacy while amplifying alternative‑treatment research. With only three scientist members remaining and their terms expiring on September 30, Delano and Cohen could become decisive votes in grant decisions. Such a shift could affect pharmaceutical companies, academic investigators, and ultimately patients seeking evidence‑based care.

The nominations reflect a growing trend of politicizing advisory panels that were once insulated from policy agendas. While NIH councils do not set health policy directly, their influence on funding pipelines can indirectly shape clinical guidelines and market dynamics. Stakeholders—research institutions, drug developers, and patient advocacy groups—should monitor the ethics review outcome and any subsequent changes to council composition. If the nominees are confirmed, the NIMH may see a recalibration of research priorities toward non‑pharmacologic interventions, prompting a reassessment of ongoing drug trials and potentially sparking legislative scrutiny of NIH appointment processes.